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Since the work ofMendel,1 genetic research has been punctuated
by key, shifting advances (box 1), which culminated in the first
draft sequence of the human genome in 2001.2-4 Although most
of the human genome sequence is shared by everyone, a small
proportion varies between individuals. This variation, acting
together with environmental factors, is thought to underlie
differences in physiology, susceptibility to disease, and
responses to drugs. We summarise the recent discoveries and
review the implications of newly acquired knowledge for
medical practice and public health.
What is known about the molecular basis
of single gene disorders?
Uncommon single gene (Mendelian) disorders such as cystic
fibrosis and familial forms of type 2 diabetes, colon cancer, and
breast cancer are caused mainly by mutations, usually in the
coding sequence of a gene, that produce a major structural or
functional disruption of an encoded protein. A mutation is both
necessary and sufficient for disease to develop, and the pattern
of disease transmission from parent to offspring is predictable.
Mendelian disorders are categorised as autosomal dominant,
autosomal recessive, or X linked, depending on whether the
mutation is located on an autosome or sex chromosome and on
whether one or two mutant alleles are needed for the disease to
manifest itself. The responsible genes were identified mainly
through analysis of DNA samples from multigenerational
families (pedigrees) with affected and unaffected members, a
technique called linkage analysis.5 6 Coinheritance of a genetic
marker of known chromosomal location with the disease
phenotype allows the position of the disease gene to be
“mapped” in these families. For some conditions, mutations in
different genes can produce the same disease phenotype, a
phenomenon known as locus heterogeneity.7 DNA sequencing
of candidate genes in the linked region allows the disease
causingmutations to be identified. For some diseases, the precise
disease causing mutations, even within the same gene, can also
differ from family to family, and this is referred to as allelic
heterogeneity.8 These discoveries provided great insight into
the normal biological function of the affected genes and proteins
and in some cases have led to the development of predictive
genetic tests, gene based or drug treatments. A comprehensive
list of single gene disorders and their molecular basis can be
found online (www.ncbi.nlm.nih.gov/omim/).
What is known about the genetic basis of
complex diseases?
Diseases that commonly affect adults (such as cardiovascular
disease, diabetes, Parkinson’s disease, Alzheimer’s disease, and
common cancers) result from amore complex interplay between
genetic and environmental factors. Such diseases exhibit familial
clustering, but there is no clear inheritance pattern because of
the polygenic aetiology and the substantial contribution from
the environment. Family based linkage analysis can rarely
identify genetic mutations associated with these disorders
because people are typically over 50 years before clinical
presentation; by this time their parents may be dead and
susceptible children too young to manifest the disorder. The
“common-disease common-variant” hypothesis proposes that
these diseases arise from many common DNA variants, each
with a modest influence on disease risk.9 10 The presence of a
particular genetic variation is neither necessary nor sufficient
to cause disease but confers a modest increase in risk.
After publication of the draft human sequence in 2001, attention
turned to cataloguing and studying the effects of common
variations in the DNA sequence on the risk of common diseases.
Single nucleotide polymorphisms (SNPs) are variations at a
single base pair (fig 1⇓) and are themost common type of human
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Summary points
Until recently the genetic basis of most common diseases remained elusive
Genome wide association analysis has now uncovered thousands of regions of human DNA where sequence variation influences
susceptibility to common diseases
Common single nucleotide polymorphisms associated with disease are distributed across multiple chromosomal regions, have modest
affects on disease risk, act additively, and explain only part of disease heritability
Association analysis is starting to provide data on the causes of common human diseases that should accelerate the design and
development of new treatments
Emerging technologies, including rapid, less costly sequencing of whole genomes, bring the prospect of better diagnostics and treatment
Clinicians will need to keep updated on genetic advances that have healthcare applications
Sources and selection criteria
Because of the wide remit of this article, we did not attempt a systematic search covering the whole of translational genetics. Instead, we
used personal collections of major journal articles and reviews accumulated individually by all authors over several years of academic work
in translational genetics.
Box 1 Key early milestones in genetic research
Discovery of nucleic acid (Meisscher 1869)
Identification of its key constituents—the organic bases adenine (A), thymine (T), guanine (G), and cytosine (C) (Kossel 1879) held on
a backbone of deoxyribose or ribose sugars in DNA and RNA, respectively
The Boveri-Sutton chromosome theory of inheritance (1902)
The proposal that DNA (not protein) is the heritable genetic material that distinguishes organisms of different species (Chargaff 1950)
The discovery of the double helical structure of DNA (Crick and Watson 1953) provided the necessary insight into how base sequence
information can be replicated and transmitted from parent to offspring. It also pointed the way to understanding how the DNA sequence
is translated into the primary amino sequence of proteins, which, in turn, determines the structure and function of an organism. The
unidirectional flow of information from DNA to RNA to protein was subsequently summarised in the central dogma (Crick 1958)
sequence variation, occurring about every 500-1000 DNA base
pairs. Less common types of variation include single nucleotide
insertions and deletions (indels) and deletion or duplication of
longer tracts of DNA (copy number variation) (fig 1).
The SNP Consortium developed the SNP database (www.ncbi.
nlm.nih.gov/SNP/) to identify the most common single
nucleotide variations in the genome. Each SNP in this database
is allocated a unique reference number. The Human HapMap
consortium (http://hapmap.ncbi.nlm.nih.gov/index.html.en) was
then established to quantify the association between SNPs in
the genomes of human populations with differing ancestry
(linkage disequilibrium). Coupled with new technological
developments, this provided the framework to develop arrays
capable of typing around 500 000 SNPs across the genome.
Information on another million or more SNPs could then be
inferred on the basis of the known associations between SNPs.
These arrays or “SNP chips” provide a cost effective way to
genotype many thousands of people. 11
To investigate the genetic basis of common diseases,
genome-wide case-control studies have compared the frequency
of typed (and inferred) SNPs in large numbers of unrelated
people affected by a disease and unaffected unrelated controls.12
Instead of the single exposure evaluated in a non-genetic
case-control study (such as smoking), these studies examine
hundreds of thousands of genetic exposures simultaneously.
Points in the genome at which the frequency of alleles differs
between cases and controls harbour the genetic variants
contributing to disease risk. Figure 2⇓ shows the results of such
a study of myocardial infarction.13 The Office of Population
Genetics website contains an up to date list of genome-wide
association studies and publications (www.genome.gov/
GWAStudies/).
Genomewide association studies involve hundreds of thousands
of tests of association, so the number of false positive
SNP-disease associations would be high if conventional
thresholds were used to determine significant associations. Thus,
stringent criteria are used before “genome-wide significance”
can be declared. Typically, P value thresholds of 1×10−7 or
5×10−8 are used.14 A P value of 5×10−8 can be thought of as a P
value of 0.05 with a Bonferroni correction for one million
statistical tests—a typical number of variants genotyped or
inferred in a genome-wide association study. Even with such
stringent thresholds, positive findings are routinely replicated
in independent datasets to confirm or refute association. Because
SNPs of smaller effect size can be identified by increasing the
available sample size, research consortiums focus on a single
disease so that data from several case-control collections can
be pooled and summarised using meta-analysis. This approach
has increased the number of genetic loci identified for many
disorders.15
How might findings from genome-wide
association studies affect healthcare?
Accumulated evidence from such studies is now helping to
determine the direction of future research and to clarify where
the future healthcare applications will be. Typically, many
genetic regions contribute to increased risk of complex disease
(20 loci have been identified for type 2 diabetes and 40 for
Crohn’s disease), but the effect at each region is weak (5-10%
increase in risk) and seems to be additive and independent. As
a result, genome wide association studies to date have explained
only a small part of the heritability of common disorders
(table⇓). The findings currently have limited value for predicting
disease risk but may have other important implications for
healthcare provision (box 2).
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Box 2 Insight into disease aetiology from genome-wide association studies
In Crohn’s disease, many of the single nucleotide polymorphisms (SNPs) associated with disease susceptibility lie in and around genes
concerned with autophagy, which was previously not considered an important disease mechanism in Crohn’s disease.
In type 2 diabetes many of the loci encode proteins concerned with insulin secretion rather than insulin signalling, which had previously been
the focus of research.
Several of the genetic loci associated with the risk of coronary heart disease influence low density lipoprotein-cholesterol, but some are
located distant from known genes and seem not to influence any of the known risk factors for myocardial infarction. Thus, previously unknown
disease mechanisms might be at work.
Data from different disorders show that some genetic regions or SNPs affect the risk of more than one disease. For example, different SNPs
in the same region on chromosome 12 influence the risk of coeliac disease, type 1 diabetes, and myocardial infarction. The same SNP near
the TCP2 gene on chromosome 8 is associated with the risk of developing type 2 diabetes and prostate cancer. These, and other examples
indicate that some common disorders have a partially overlapping aetiological basis, and this may lead to new disease taxonomy.
Can genetics help predict risk of common
disease?
Predictive genetic tests based on findings from genome-wide
association studies are being offered commercially, despite
concerns about their clinical value.16 17 With a few notable
exceptions (such as age related macular degeneration18; table),
carrying any one common risk allele increases the chance of
experiencing a common disease event by only a fraction
(typically 5-25%). This makes tests based on only one SNP
poorly predictive. Several risk alleles, often on different genes,
may contribute to increased risk of disease, so would information
from a panel of common modest effect alleles be better at
predicting disease than a single common risk allele? A person
with 10 risk alleles, each in a different gene and each conferring
a 20% increase in risk, might be expected to be at double the
risk of disease compared with someone carrying none, and such
a high risk person might benefit from a targeted preventive
intervention. However, people with 10 risk alleles are rare in
the population. For example, if the average frequency of a risk
allele in a population is 30% (0.3), the probability of inheriting
10 such independent alleles is 0.310 (0.0000059). Because the
frequency distribution of common independently inherited risk
alleles is normal (bell shaped) and the association with risk is
additive, more cases of disease would be expected in the many
people with an intermediate number of risk alleles than the
minority with a large number of alleles. Thus, the frequency
distributions of risk alleles should overlap substantially among
eventual cases and controls, making it difficult to separate the
two groups by the number of risk alleles carried (fig 3⇓).
In disease prevention the aim is often to stratify risk rather than
to discriminate events. This is because many preventive
interventions produce the same relative risk reduction whatever
the risk so that the absolute benefit is larger (and the number
needed to treat smaller) in people at high risk. If the number
needed to treat to prevent one event in a person with 10 risk
alleles was 100, the number needed to screen to prevent one
event would be 100/0.000006 (16 666 666). Although genotype
based tests are cheap, screening such a large number of people
just to alter risk of disease in one would be very costly.
Genetic tests that capture a wider range of variability in a given
gene or region, rather than simply a few SNPs, may be better
for prediction. The discovery of rare or intermediate frequency
alleles that have amuch larger effect size than commonHapMap
alleles may also open up greater opportunities.20 Tests of rarer
alleles may be useful in family based screening, such as that
used for monogenic familial hypercholesterolaemia, which
currently uses cholesterol measurement rather than genotyping.21
Can genetics improve understanding of
the non-genetic causes of disease?
The genotype is unique among naturally occurring differences
between people because it is allocated at random,1 fixed
throughout life, and not modified by disease. Interpretation of
genetic associations is therefore not limited by confounding
(where exposure and disease seem to be associated because of
common association with a third factor) or reverse causation
(where the association between an exposure and disease is
caused by the disease itself leading to an alteration in the
exposure).22-24 Thus when the function of a gene is known, its
association with a disease (however weak) can provide clear
insight into the causal mechanisms leading to disease (fig 4⇓).
For example, ADH1 (alcohol dehydrogenase) gene variants are
associated with differences in long term alcohol consumption,
which is otherwise difficult to measure accurately. ADH1
variants can provide a useful index of long term usual alcohol
consumption. Association between these variants and
oesophageal cancer provides evidence for a causal role of
alcohol consumption in the disease.25 Another example is C
reactive protein (CRP) and its role in coronary heart disease.
Raised concentrations of CRP are associated with an increased
risk of heart disease. However, bias and confounding by reverse
causality may partially or wholly explain these associations, so
we do not know whether lowering CRP would reduce the risk
of cardiovascular events. Genetic variants that influence CRP
values are less prone to confounding, and reverse causality is
not a problem. The presence or absence of an association
between CRP genetic variants and disease can thus provide clear
evidence on whether CRP actually plays a causal role in
disease.26 27
Can genetics lead to improved
therapeutics?
Using pharmacogenetics to develop genotype based predictive
tests of drug response may help to personalise or stratify
therapeutic interventions at an individual or group level. The
number of pharmacogenetic tests currently approved for clinical
use is limited. A recent systematic review of pharmacogenetic
studies highlighted several methodological and other problems
in this area,29 notably small underpowered studies and the
widespread use of surrogate outcome measures. However,
genetic loci associated with the risk of statin myopathy have
recently been identified,30 as well as loci associated with
hypersensitivity to the protease inhibitor abacavir,31 response
to interferon treatment in hepatitis C infection,32 and dose
requirements in people taking warfarin.33 Pharmacogenetic
testing may eventually become common in some therapeutic
areas, but the clinical value and cost effectiveness of emergent
pharmacogenetic tests have not yet been subject to the same
level of scrutiny and careful appraisal as other diagnostic tests.
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As well as offering the potential for new pharmacogenetic tests,
emerging genome-wide association studies of drug response
could provide new insights into the pathways by which even
well established drugs are handled by the body. The concept of
pharmacogenetics is expanding to incorporate not only the use
of genetic data to guide treatment but also to inform drug
development. This is because studies in populations of variants
in genes encoding a drug target protein can be considered to be
a type of natural randomised trial and could be used to help
predict the on-target effect of modifying the same target
pharmacologically. For example, common variants in theCETP
gene, which encodes cholesteryl ester transfer protein, the target
of the CETP inhibitor torcetrapib, were associated with the same
lipid and lipoprotein changes seen with torcetrapib treatment
but were not associated with high blood pressure, an off-target
effect of torcetrapib.34 The hope is that by providing randomised
evidence of the effects of drugs in humans without requiring
participants’ exposure to a new molecule of uncertain safety
and efficacy new drug targets might be validated and the risks
of late stage failure in drug development reduced through the
application of genetic studies during early drug development.
Future directions
Much of the heritability of common diseases cannot be explained
by common SNPs, so the focus is now moving towards other
types of genetic variation, such as copy number and rare single
nucleotide variation. Interest in heritable changes in gene
expression caused by other processes, such as DNAmethylation
or histone modification, is also increasing.20 35
Some alleles with large effects on disease risk are likely to be
rare (because natural selection reduces their frequency over
time) and thus are not well represented on whole genome arrays.
Efforts in this area are being stimulated by another technological
advance, the ability to sequence a single human genome (exome
sequencing) using “next generation” sequencing technology. In
contrast to the first draft human genome sequence, which took
several years and millions of pounds to complete, this now takes
a few days and costs about £8000 (€9000; $12 600). Systematic
rare variant discovery is now being undertaken as part of the
international 1000 genomes project (www.1000genomes.org/
page.php) and the UK 10k Consortium. Whole exome
sequencing is expected to identify rare variants that influence
risk in common disorders and identify mutations underlying
sporadic single gene disorders that have not been amenable to
linkage analysis because of the absence of multigenerational
pedigrees. The variants that are discoveredmay eventually prove
valuable as family based genetic tests.
Finally, analysis of the effects of newly discovered genetic loci
in representative population based cohort studies (not
case-control studies) are beginning to provide better information
on the absolute (not relative) risk of common diseases, as well
as insight into the modification of genetic effects by
environmental factors. The UK Biobank project (www.
ukbiobank.ac.uk/)—a prospective study that has recruited more
than 500 000 volunteers, stored millions of biological samples
(including DNA), and recorded information on lifestyle
measures—will provide a new resource for scientists studying
the environmental and genetic determinants of a wide range of
common diseases in future decades.
Conclusions
As the use of whole genome sequencing becomes more
widespread, an improved understanding of the causes of disease,
better targeted drug treatments, and perhaps prediction of risk
are realistic expectations. As in any area of medical advance,
rigorous evaluation of new genetic based technologies will be
needed. Amajor challenge for clinicians will be to keep updated
on genetic advances with potential healthcare applications and
to develop the ability to critically appraise research findings in
this fast moving field.
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Glossary
Allele: Alternative forms of a genetic locus; a single allele for each locus is inherited separately from each parent
Autosome: A chromosome not involved in sex determination
Complex disease genetics: The study of the patterns of inheritance of common diseases resulting from the combined action of alleles
of more than one gene (such as heart disease, diabetes, and some cancers)
Epigenetics: The study of heritable changes in gene expression that are not caused by changes in DNA sequence
Genotype: The specific combination of two alleles inherited for a particular gene
Human genome: The total set of chromosomes found in an individual
Linkage analysis: Analysis of DNA markers that are near or within a gene of interest among families to identify the inheritance of a
disease causing mutation in a given gene
Linkage disequilibrium: Where alleles occur together more often than can be accounted for by chance alone
Locus: The physical position of a gene or marker on a chromosome
Marker: An identifiable physical location on a chromosome (for example, a single nucleotide polymorphism or a gene), the inheritance
of which can be assessed. Markers can be regions of DNA that are expressed (genes) or a segment of DNA with no known coding
function but whose pattern of inheritance can be determined
Mutation: Any heritable change in DNA sequence that occurs in less than 1% of the population
Phenotype: The observable characteristics of an organism produced by the genotype (or environment, or both)
Sex chromosome: The X and Y chromosomes in humans that determine sex
Single nucleotide polymorphism (SNP): Variation at a single base pair (A, T, C, or G) in the DNA sequence
The SNP Consortium: A public-private partnership that was established to identify and map common SNPs. As part of the international
HapMap project, it aimed to generate a high quality, extensive, publicly available map of SNPs as markers evenly distributed throughout
the human genome in different populations
Additional educational resources
Resources for healthcare professionals
Online Mendelian Inheritance in Man (OMIM) (www.ncbi.nlm.nih.gov/omim)—Comprehensive database of human genes and genetic
phenotypes that contains information on all known mendelian disorders and more than 12 000 genes
The SNP Consortium Database (www.ncbi.nlm.nih.gov/SNP/)—National Center for Biotechnology Information database of all known
single nucleotide polymorphisms
Human HapMap Consortium (http://hapmap.ncbi.nlm.nih.gov/index.html.en)—Public resource developed by a partnership of scientists
and funding agencies to help researchers find genes associated with human disease
Office of Population Genetics (www.genome.gov/GWAStudies/)—Catalogue of published genome wide association studies
1000 Genomes Project (www.1000genomes.org/page.php)—Catalogue of human genetic variation
UK Biobank Project (www.ukbiobank.ac.uk/)—Resource to support a diverse range of research intended to improve the prevention,
diagnosis, and treatment of illness, and the promotion of health
Resources for patients and the public
BBC Frontiers (www.bbc.co.uk/programmes/b00vkxy0)—BBC Radio 4 documentary about PLX4032, a new cancer drug based on new
genetic knowledge
Wellcome Trust Centre for Human Genetics: Understanding human genetics (www.well.ox.ac.uk/monaco/Group/Complex_Disorders.
shtml)—Good introduction to genetics
NHS National Genetics Education and Development Centre (www.geneticseducation.nhs.uk/)—Includes a wide range of introductory
material about many areas of genetics
NHS Choices (www.library.nhs.uk/GENETICCONDITIONS/ViewResource.aspx?resID=287600&tabID=289&catID=8700)—Site that
discusses and analyses news stories on genetic breakthroughs
NHS UKGenetic Testing Network (www.ukgtn.nhs.uk/gtn/Home/Public)—Advises the NHS on all aspects of genetic testing; this section
for the public has links to a range of other resources
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Table
Table 1| Recently identified genetic variants associated with disease*
Insight on mechanismExamples of associated genesExamples of research consortiumsDisease
Autophagy, immunityNOD2, IRGM, ATG16L1, IL23R, PTPN2,
PTGER4
WTCCCCrohn’s disease
Insulin secretion unknownTCF7L2, CAPN10, VNTR, SLC2A2, IRS1,
CDKAL1, FTO, CDKN2B
DIAGRAM WTCCC DGIType 2 diabetes
Low density lipoprotein-cholesterol
pathway unknown
APOE, PCSK9, CELSR2/PSRC1,
CDKN2A/CDKN2B
CARDIOGRAM WTCCCMyocardial infarction and coronary
heart disease
Complement pathway, high density
lipoprotein-cholesterol pathway?
CFH, C2/CFB, C3, CFI, ARMS2, TIMP3,
LIPC, CETP, LPL, ABCA1
Age related macular disease
DNA and cell repair, tumour suppression
pathway
BRCA1, BRCA2, PTEN, TP53, FGFR2,
TNRC9
Asia Breast Cancer ConsortiumBreast cancer
Complement pathwayCFH/CFHR3International Meningococcal Genetics
Consortium
Meningococcal disease
As yet unknownGATA6, CTAGE1, RBBP8, CABLES1African Tuberculosis Genetics
Consortium and WTCCC
Tuberculosis
*The variants vary in their strength of effect. Some variants (such as BRCA1 in breast cancer and CFH in age related macular disease) are strongly associated
with disease risk and thus highly predictive of disease risk, whereas others (such as those listed for myocardial infarction and coronary heart disease) are only
weakly associated with disease risk and provide little predictive power.
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Figures
Fig 1 The spectrum of common genetic variation includes single nucleotide polymorphism, insertion and deletion
polymorphism, nucleotide repeat polymorphism, and copy number variation, all of which may affect coding or non-coding
regions of DNA
Fig 2Manhattan plot from a genome-wide association study of myocardial infarction (adapted, with permission, from Samani
and colleagues13). The x axis refers to points along the genome (separated by chromosome) at which each of the several
hundred thousand single nucleotide polymorphisms (SNPs; represented by a dot) evaluated are located. The y axis refers
to the negative logarithm of the P value for a test of association between each SNP and the binary outcome—the presence
or absence of disease. For example, a −log P value of 7 (shown by the dashed red line) equates to a P value for the
association of an SNP with disease of 1×10−7 or 0.0000001, and a −log P value of 7.3 equates to 5×10−8
Fig 3 Association between the population frequency distribution of type 2 diabetes risk alleles (bars) and risk of incident
diabetes (red line) in the Whitehall II study (adapted from Talmud and colleagues19)
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Fig 4 Conceptual parallels between a randomised controlled trial and a Mendelian randomisation experiment to judge the
causal relevance of a biomarker associated with risk of cardiovascular disease (adapted from Casas and colleagues28)
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